Skip to main content
$45.88 $0.19 (0.4%)

04:00 PM EST on 01/14/22

Cassava Sciences, Inc. (NASDAQ:SAVA)

CAPS Rating: 1 out of 5

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease.

Current Price $45.88 Mkt Cap $1.8B
Open $44.93 P/E Ratio 0.00
Prev. Close $45.88 Div. (Yield) $0.00 (0.0%)
Daily Range $44.10 - $46.43 Volume 1,413,152
52-Wk Range $10.90 - $146.16 Avg. Daily Vol. 3,259,086

Caps

How do you think NASDAQ:SAVA will perform against the market?

Add Stock to CAPS Watchlist

All Players

192 Outperform
35 Underperform
 

All-Star Players

26 Outperform
10 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:SAVA Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

kmhjv3rt (< 20)
Submitted December 21, 2021

Cassava Sciences shares are trading higher after the company was informed by Neuroscience journal that there was no evidence to support data manipulation claims in a 2005 company-authored paper.

naughtyguy (37.23)
Submitted March 20, 2021

This is WAY overbought!

Recent Community Commentary

Read the most recent pitches from players about SAVA.

Recs

1
Member Avatar kmhjv3rt (< 20) Submitted: 12/21/2021 10:49:03 AM : Outperform Start Price: $41.31 NASDAQ:SAVA Score: +9.58

Cassava Sciences shares are trading higher after the company was informed by Neuroscience journal that there was no evidence to support data manipulation claims in a 2005 company-authored paper.

Recs

1
Member Avatar TMFjimhalley (< 20) Submitted: 7/12/2021 6:46:55 PM : Outperform Start Price: $100.15 NASDAQ:SAVA Score: -60.61

The potential for growth in Alzheimer's drugs is huge as our population ages. Cassava has a diagnostic blood test for Alzheimer's in the works and a therapy to treat the disease also in trials.

Recs

1
Member Avatar naughtyguy (37.23) Submitted: 3/20/2021 3:39:38 PM : Underperform Start Price: $57.03 NASDAQ:SAVA Score: +38.51

This is WAY overbought!

Leaderboard

Find the members with the highest scoring picks in SAVA.

Score Leader

medeaschild

medeaschild (65.74) Score: +5,848.79

The Score Leader is the player with the highest score across all their picks in SAVA.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
medeaschild 65.74 12/26/2018 Outperform NS $0.76 +5,945.73% +96.95% +5,848.79 0 Comment
SmallCapSurfer2 92.13 10/13/2016 Outperform 3M $5.32 +764.47% +119.05% +645.42 0 Comment
capptten < 20 12/1/2020 Outperform 3M $7.66 +500.39% +27.13% +473.26 1 Comment
foolrrrrrrrrrr 34.31 11/13/2008 Underperform 1Y $37.61 +22.29% +464.22% +441.93 0 Comment
marcet 74.62 3/2/2009 Underperform 3W $18.82 +144.31% +552.21% +407.90 0 Comment
Dennyf10 63.11 10/16/2008 6/22/2009 Underperform 1Y $35.72 +28.73% +420.86% +392.12 0 Comment
jornoski 31.68 9/21/2020 Outperform 5Y $9.45 +386.67% +42.69% +343.98 0 Comment
OklaBoston 62.33 9/21/2020 Outperform 3Y $9.45 +386.67% +42.69% +343.98 1 Comment
hackerbobZ < 20 3/23/2009 Underperform 5Y $17.65 +160.53% +496.39% +335.86 0 Comment
clangmead 51.51 1/19/2021 Outperform 5Y $10.38 +343.06% +22.84% +320.23 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for SAVA.